Stock MCRB SERES THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Real-time Estimate Cboe BZX
Other stock markets
 02:14:50 2024-06-10 pm EDT 		5-day change 1st Jan Change
0.781 USD +27.20% Intraday chart for Seres Therapeutics, Inc. -24.29% -41.59%
Jun. 07 Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $10 From $15, Maintains Buy Rating MT
Jun. 07 Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $10 From $15, Maintains Buy Rating
MT
SERES THERAPEUTICS ENTERS INTO MEMORANDUM OF UNDERSTANDING FOR VOWST ASSET SALE TO NESTLE HEALTH SCIENCE
AQ
Seres Therapeutics - Nestle Health Science agrees to acquire global rights to VOWST, product it launched in June 2023
AQ
Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target
MT
Chardan Adjusts PT on Seres Therapeutics to $1.25 From $6 on Heels of Announced MoU With Nestle for Sale of VOWST Assets; Maintains Buy Rating
MT
Nestlé Unit to Buy Vowst Assets from Seres Therapeutics
MT
Sector Update: Health Care Stocks Advance Thursday Afternoon
MT
Seres Therapeutics to Sell Vowst Assets to Nestle Health Science
MT
Nestlé: acquisition of a drug derived from microbiota
CF
Nestle's health arm to buy first-ever fecal transplant pill
RE
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
PR
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
AQ
Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating
MT
Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating
MT
Transcript : Seres Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
Seres Therapeutics: Q1 Earnings Snapshot
AQ
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
BU
Seres Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Seres Therapeutics : Accelaration/Increase of Financial Obligation - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MCRB Stock
  4. News Seres Therapeutics, Inc.